Okuni Marika, Yakushijin Kimikazu, Uehara Keiichiro, Ichikawa Hiroya, Suto Hirotaka, Hashimoto Akiko, Tanaka Yasuhiro, Shinzato Isaku, Sakai Rina, Mizutani Yu, Nagao Shigeki, Kurata Keiji, Kakiuchi Seiji, Miyata Yoshiharu, Inui Yumiko, Saito Yasuyuki, Kawamoto Shinichiro, Yamamoto Katsuya, Ito Mitsuhiro, Matsuoka Hiroshi, Minami Hironobu
The Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital, Japan.
Department of Diagnostic Pathology, Kobe University Hospital, Japan.
Intern Med. 2019 Mar 1;58(5):707-712. doi: 10.2169/internalmedicine.1266-18. Epub 2018 Nov 19.
A 45-year-old woman was diagnosed with hepatosplenic T-cell lymphoma (HSTCL), a rare subtype of peripheral T-cell lymphoma. She received different types of chemotherapy, but disease progression was observed. To reduce the tumor burden before an unrelated bone marrow transplantation, combination chemotherapy consisting of the gemcitabine, carboplatin, and dexamethasone (GCD) was administered as bridging therapy, resulting in a reduction in the number of lymphoma cells. We were then able to perform bone marrow transplantation. Although she experienced some adverse events, she successfully achieved long-term remission. We herein report a successful case of HSTCL treated with unrelated stem cell transplantation following the GCD regimen as bridging chemotherapy.
一名45岁女性被诊断为肝脾T细胞淋巴瘤（HSTCL），这是外周T细胞淋巴瘤的一种罕见亚型。她接受了不同类型的化疗，但疾病仍有进展。为了在非亲缘骨髓移植前减轻肿瘤负荷，给予吉西他滨、卡铂和地塞米松（GCD）组成的联合化疗作为桥接治疗，使淋巴瘤细胞数量减少。随后我们得以进行骨髓移植。尽管她经历了一些不良事件，但成功实现了长期缓解。我们在此报告一例采用GCD方案作为桥接化疗后进行非亲缘干细胞移植治疗HSTCL的成功病例。
